Bevacizumab-Irinotecan combination therapy in recurrent low-grade glioma, previously treated with chemo-radiotherapy: a case report

Frontiers in Oncology

Oncology

Barbara Castelli¹  Milena Guidi¹  Carla Fonte²  Marco Tellini²  Iacopo Sardi²  Marco Di Nicola²  Lorenzo Genitori³  Anna Maria Buccoliero⁴  Alessandro Iacono⁵  Daniela Greto⁶ 

[1] Health Sciences Department, University of Florence, Florence, Italy;Neuro-Oncology Unit, Meyer Children’s Hospital Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), Florence, Italy;Neuro-Oncology Unit, Meyer Children’s Hospital Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), Florence, Italy;Neurosurgery Unit, Meyer Children’s Hospital Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), Florence, Italy;Pathology Unit, Meyer Children’s Hospital Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), Florence, Italy;Radiology Unit, Meyer Children’s Hospital Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), Florence, Italy;Radiotherapy Unit, University of Florence, Florence, Italy;

关键词: low-grade gliomas;    bevacizumab;    irinotecan;    pilocytic astrocytoma;    case report;   

DOI  :  10.3389/fonc.2023.1244628

 received in 2023-06-22, accepted in 2023-08-14,  发布年份 2023

来源: Frontiers

【 摘 要 】

Low grade gliomas (LGGs) of pineal region are usually difficult to remove and they frequently relapse or progress after front line chemotherapy. Bevacizumab-Irinotecan (BEVIRI) combination has been successfully attempted in children with recurrent LGGs, in most cases not previously irradiated. The efficacy of bevacizumab has also been described in radiation necrosis. Considering the possible overlapping of radiation treatment effect and disease progression and difficulty in differentiating, we report on the use of BEVIRI in a case of a recurrent relapsing low-grade glioma of the pineal region, subjected to multiple neurosurgical interventions, also treated with a carboplatin-etoposide regimen and a radiation course, at present at one-year follow-up showing a stable response, with no adverse events.

【 授权许可】

Unknown   
Copyright © 2023 Castelli, Fonte, Guidi, Tellini, Di Nicola, Iacono, Buccoliero, Greto, Genitori and Sardi

【 图 表 】

fonc-13-1244628-i001.tif